|
306 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...1213141516171819202122...9899» |
- sorafenib / Generic mfg.
Trial completion, Enrollment change, Metastases: Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer (clinicaltrials.gov) - Mar 4, 2016
P1, N=8, Completed, Sponsor: Polaris Group
Active, not recruiting --> Completed | N=21 --> 8
- morphine sulphate / Generic mfg.
Biomarker, Trial completion, Enrollment change, Trial primary completion date: Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease (clinicaltrials.gov) - Mar 4, 2016
P1, N=22, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed | N=21 --> 8 Recruiting --> Completed | N=30 --> 22 | Trial primary completion date: Oct 2013 --> Mar 2014
- || grazoprevir (MK-5172) / Merck (MSD), ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial primary completion date: Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Na (clinicaltrials.gov) - Mar 2, 2016
P2, N=368, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | N=30 --> 22 | Trial primary completion date: Oct 2013 --> Mar 2014 Trial primary completion date: Jun 2012 --> Mar 2015
- Enrollment change, Trial termination: Factors Associated With End Stage Liver Disease (clinicaltrials.gov) - Mar 2, 2016
P=N/A, N=27, Terminated, Sponsor: New York University School of Medicine
Trial primary completion date: Jun 2012 --> Mar 2015 N=100 --> 27 | Recruiting --> Terminated
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Enrollment change, Trial withdrawal: A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure (clinicaltrials.gov) - Mar 2, 2016
P3, N=0, Withdrawn, Sponsor: New York University School of Medicine
N=100 --> 27 | Recruiting --> Terminated N=70 --> 0 | Not yet recruiting --> Withdrawn
- | Pegasys (pegylated interferon α -2a) / Roche
Trial completion, Combination therapy: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program. (clinicaltrials.gov) - Mar 2, 2016
P4, N=48, Completed, Sponsor: Hoffmann-La Roche
N=70 --> 0 | Not yet recruiting --> Withdrawn No longer recruiting --> Completed
- Trial primary completion date: CETRA: Cirrhosis, Effects of TRAnsplantation and Diabetes (clinicaltrials.gov) - Mar 1, 2016
P=N/A, N=200, Recruiting, Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
No longer recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- Trial completion, Trial primary completion date: Prevalence of Colon Cancer in Pyogenic Liver Abscess (clinicaltrials.gov) - Mar 1, 2016
P4, N=62, Completed, Sponsor: Inje University
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Feb 2016
- Trial completion, Enrollment change, Trial primary completion date: Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver! (clinicaltrials.gov) - Mar 1, 2016
P=N/A, N=81, Completed, Sponsor: Bram Brouwers
Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Feb 2016 Recruiting --> Completed | N=114 --> 81 | Trial primary completion date: Mar 2014 --> Nov 2015
- ||||||| tenofovir disoproxil fumarate / Generic mfg.
Trial completion: Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection (clinicaltrials.gov) - Mar 1, 2016
P3, N=106, Completed, Sponsor: Gilead Sciences
Recruiting --> Completed | N=114 --> 81 | Trial primary completion date: Mar 2014 --> Nov 2015 Active, not recruiting --> Completed
- Trial primary completion date: Mediterranean Lifestyle Intervention in Patients With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - Feb 29, 2016
P=N/A, N=75, Recruiting, Sponsor: Harokopio University
Active, not recruiting --> Completed Trial primary completion date: Sep 2015 --> Mar 2016
- ||||||| Trial completion: Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) (clinicaltrials.gov) - Feb 27, 2016
P3, N=151, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Sep 2015 --> Mar 2016 No longer recruiting --> Completed
- carvedilol / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis. (clinicaltrials.gov) - Feb 27, 2016
P=N/A, N=84, Recruiting, Sponsor: Institute of Liver and Biliary Sciences, India
No longer recruiting --> Completed Withdrawn --> Recruiting | Initiation date: Aug 2012 --> Feb 2016 | Trial primary completion date: Aug 2014 --> Dec 2017
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed, Enrollment change: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting (clinicaltrials.gov) - Feb 27, 2016
P2, N=19, Active, not recruiting, Sponsor: Gilead Sciences
Withdrawn --> Recruiting | Initiation date: Aug 2012 --> Feb 2016 | Trial primary completion date: Aug 2014 --> Dec 2017 Recruiting --> Active, not recruiting | N=25 --> 19
- Enrollment closed, Trial primary completion date, Combination therapy, Monotherapy: Tenofovir DF With or Without Peginterferon for Chronic Hepatitis B (clinicaltrials.gov) - Feb 26, 2016
P3, N=26, Active, not recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Active, not recruiting | N=25 --> 19 Recruiting --> Active, not recruiting | Trial primary completion date: May 2020 --> Mar 2013
- ribavirin / Generic mfg.
Trial completion, Trial primary completion date: Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4 (clinicaltrials.gov) - Feb 25, 2016
P4, N=181, Completed, Sponsor: King Abdulaziz Medical City
Recruiting --> Active, not recruiting | Trial primary completion date: May 2020 --> Mar 2013 Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Aug 2015
- | Glypressin (terlipressin) / Ferring
Trial completion, Trial primary completion date: Terlipressin in Septic Shock in Cirrhosis (clinicaltrials.gov) - Feb 25, 2016
P2/3, N=72, Completed, Sponsor: Hospital Clinic of Barcelona
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Aug 2015 Recruiting --> Completed | Trial primary completion date: Oct 2009 --> Dec 2012
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD), Isentress (raltegravir) / Merck (MSD)
Enrollment change: Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds (clinicaltrials.gov) - Feb 24, 2016
P4, N=20, Completed, Sponsor: Johns Hopkins University
Recruiting --> Completed | Trial primary completion date: Oct 2009 --> Dec 2012 N=40 --> 20
- Trial completion: HBVSECURE: Assessment and Monitoring of Renal Proximal Tubular Tolerance of Nucleoside and Nucleotide Analogues Using Early Screening Tools in Patients Chronically Mono-infected With Hepatitis B Virus (clinicaltrials.gov) - Feb 24, 2016
P=N/A, N=216, Completed, Sponsor: University Hospital, Limoges
N=40 --> 20 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: HCV/HIV Coinfection: Antiviral Therapy and Fibrosis (clinicaltrials.gov) - Feb 24, 2016
P=N/A, N=1250, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Oct 2018 --> Oct 2015
- avadomide (CC-122) / BMS
Phase classification, Combination therapy: Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer (clinicaltrials.gov) - Feb 24, 2016
P1, N=40, Recruiting, Sponsor: Celgene Corporation
Recruiting --> Completed | Trial primary completion date: Oct 2018 --> Oct 2015 Phase classification: P1b --> P1
- | Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: Simeprevir in Combination With Sofosbuvir in Treatment-Na (clinicaltrials.gov) - Feb 24, 2016
P2, N=30, Completed, Sponsor: Peter J. Ruane, M.D.
Phase classification: P1b --> P1 Recruiting --> Completed
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Trial completion, Enrollment change: Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement (clinicaltrials.gov) - Feb 24, 2016
P=N/A, N=136, Completed, Sponsor: Mette Munk Lauridsen
Recruiting --> Completed Active, not recruiting --> Completed | N=250 --> 136
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Metastases: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Feb 23, 2016
P2, N=299, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=250 --> 136 Trial primary completion date: Feb 2016 --> Jun 2016
- MBL-HCV1 / MassBiologics
Trial termination: Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C (clinicaltrials.gov) - Feb 23, 2016
P2, N=11, Terminated, Sponsor: MassBiologics
Trial primary completion date: Feb 2016 --> Jun 2016 Completed --> Terminated; The study was terminated due to slower than anticipated subject accrual.
- Trial suspension, Trial primary completion date: Mesenchymal Stem Cells Treat Liver Cirrhosis (clinicaltrials.gov) - Feb 23, 2016
P1/2, N=200, Suspended, Sponsor: Yufang Shi
Completed --> Terminated; The study was terminated due to slower than anticipated subject accrual. Recruiting --> Suspended | Trial primary completion date: Dec 2010 --> Dec 2017
- |||| Olysio (simeprevir) / J&J, Medivir
Trial completion, HEOR: A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir (clinicaltrials.gov) - Feb 22, 2016
P4, N=315, Completed, Sponsor: Janssen Scientific Affairs, LLC
Recruiting --> Suspended | Trial primary completion date: Dec 2010 --> Dec 2017 Active, not recruiting --> Completed
- ||||| Zepatier (grazoprevir/elbasvir) / Merck (MSD)
Enrollment closed, Trial primary completion date: Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Na (clinicaltrials.gov) - Feb 22, 2016
P3, N=453, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Apr 2017
- arsenic trioxide / Generic mfg.
P2 data, Enrollment change, Trial primary completion date, Metastases: A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver (clinicaltrials.gov) - Feb 21, 2016
P2, N=9, Terminated, Sponsor: The University of Texas Medical Branch, Galveston
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Apr 2017 N=30 --> 9 | Trial primary completion date: Aug 2012 --> Apr 2010
- |||| Pegasys (pegylated interferon ? -2a) / Roche
Trial completion, Combination therapy: ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection. (clinicaltrials.gov) - Feb 21, 2016
P4, N=1469, Completed, Sponsor: Hoffmann-La Roche
N=30 --> 9 | Trial primary completion date: Aug 2012 --> Apr 2010 No longer recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: The Feasibility of Using Anesthesia and Suspended Ventilation to Immobilize Liver Tumors During Radiotherapy (clinicaltrials.gov) - Feb 18, 2016
P=N/A, N=10, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed | N=26 --> 10 | Trial primary completion date: Oct 2016 --> Feb 2016
- Trial primary completion date: INFECIR2: The INFECIR-2 Albumin Prevention Study (clinicaltrials.gov) - Feb 18, 2016
P4, N=512, Recruiting, Sponsor: EASL - CLIF Consortium
Active, not recruiting --> Completed | N=26 --> 10 | Trial primary completion date: Oct 2016 --> Feb 2016 Trial primary completion date: Dec 2015 --> Dec 2017
- ||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Enrollment change: DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (clinicaltrials.gov) - Feb 18, 2016
P3, N=310, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Trial primary completion date: Dec 2015 --> Dec 2017 N=458 --> 310
- Trial completion, Enrollment change: A Trial to Study the Influence of Growth Factors on Bone Marrow and Hepatic Regeneration in Patients With Decompensated Cirrhosis. (clinicaltrials.gov) - Feb 18, 2016
P=N/A, N=60, Completed, Sponsor: Institute of Liver and Biliary Sciences, India
N=458 --> 310 Recruiting --> Completed | N=100 --> 60
- metformin / Generic mfg.
Trial completion, Enrollment change: Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance (clinicaltrials.gov) - Feb 17, 2016
P=N/A, N=86, Completed, Sponsor: Institute of Liver and Biliary Sciences, India
Recruiting --> Completed | N=100 --> 60 Recruiting --> Completed | N=126 --> 86
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Trial completion, Enrollment change: Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy. (clinicaltrials.gov) - Feb 17, 2016
P=N/A, N=73, Completed, Sponsor: Institute of Liver and Biliary Sciences, India
Recruiting --> Completed | N=126 --> 86 Recruiting --> Completed | N=50 --> 73
- Trial primary completion date: Clinical Trial Study About Human Adipose-Derived Stem Cells in the Liver Cirrhosis (clinicaltrials.gov) - Feb 17, 2016
P1, N=6, Recruiting, Sponsor: Gwo Xi Stem Cell Applied Technology Co., Ltd.
Recruiting --> Completed | N=50 --> 73 Trial primary completion date: Jul 2016 --> Jul 2017
- |||| faldaprevir (BI201335) / Boehringer Ingelheim, deleobuvir (BI 207127) / Boehringer Ingelheim
Trial primary completion date, Combination therapy: Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2 (clinicaltrials.gov) - Feb 12, 2016
P3, N=496, Completed, Sponsor: Boehringer Ingelheim
Trial primary completion date: Jul 2016 --> Jul 2017 Trial primary completion date: Jan 2015 --> Feb 2014
- Trial completion, Enrollment change, Trial primary completion date: Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease (clinicaltrials.gov) - Feb 11, 2016
P=N/A, N=147, Completed, Sponsor: Institute of Liver and Biliary Sciences, India
Trial primary completion date: Jan 2015 --> Feb 2014 Recruiting --> Completed | N=856 --> 147 | Trial primary completion date: May 2016 --> Dec 2015
- ||| Prolastin-C (human alpha1-proteinase inhibitor IV) / Grifols, OrphanPacific
Enrollment closed: Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus (clinicaltrials.gov) - Feb 11, 2016
P2, N=76, Active, not recruiting, Sponsor: Grifols Therapeutics Inc.
Recruiting --> Completed | N=856 --> 147 | Trial primary completion date: May 2016 --> Dec 2015 Recruiting --> Active, not recruiting
- Trial primary completion date: A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis (clinicaltrials.gov) - Feb 11, 2016
P=N/A, N=370, Recruiting, Sponsor: George Washington University
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2015 --> Jun 2016
- Trial completion, Enrollment change, Trial primary completion date: The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System (clinicaltrials.gov) - Feb 10, 2016
P=N/A, N=20, Completed, Sponsor: George Washington University
Trial primary completion date: Nov 2015 --> Jun 2016 Recruiting --> Completed | N=30 --> 20 | Trial primary completion date: Sep 2015 --> Jun 2015
- Enrollment closed, Trial primary completion date: Effect of 4 Liver Fibrosis Tests (PIIINP, CIV, LN, and HA) on the Prognosis of Liver Cirrhosis (clinicaltrials.gov) - Feb 10, 2016
P=N/A, N=100, Active, not recruiting, Sponsor: General Hospital of Shenyang Military Region
Recruiting --> Completed | N=30 --> 20 | Trial primary completion date: Sep 2015 --> Jun 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jun 2016
- Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
Enrollment change, Trial termination, Trial primary completion date: Compassionate Use of Omegaven IV Fat Emulsion (clinicaltrials.gov) - Feb 10, 2016
P2, N=15, Terminated, Sponsor: Cindy Haller
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jun 2016 N=50 --> 15 | Recruiting --> Terminated | Trial primary completion date: Jun 2014 --> Feb 2014
- ornithine phenylacetate oral (MNK-6106) / Mallinckrodt
Trial primary completion date: STOP-ALF: Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury (clinicaltrials.gov) - Feb 9, 2016
P2, N=36, Recruiting, Sponsor: William Lee
N=50 --> 15 | Recruiting --> Terminated | Trial primary completion date: Jun 2014 --> Feb 2014 Trial primary completion date: Jun 2016 --> Sep 2017
- | alpha-1-antitrypsin inhalation (VR179) / Vectura, Grifols
Enrollment change: Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Feb 9, 2016
P2, N=30, Completed, Sponsor: Grifols Therapeutics Inc.
Trial primary completion date: Jun 2016 --> Sep 2017 N=41 --> 30
- baclofen / Generic mfg.
Trial completion: BRAC: Baclofen to Reduce Alcohol Use in Veterans With HCV (clinicaltrials.gov) - Feb 9, 2016
P4, N=180, Completed, Sponsor: VA Office of Research and Development
N=41 --> 30 Active, not recruiting --> Completed
- |||| emricasan (IDN 6556) / Histogen, Amerimmune
Trial completion: A Study of IDN-6556 in Subjects With Liver Cirrhosis (clinicaltrials.gov) - Feb 8, 2016
P2, N=87, Completed, Sponsor: Conatus Pharmaceuticals Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Fendrix (hepatitis B (rDNA) vaccine adjuvanted, adsorbed) / GSK, Engerix-B (hepatitis B vaccine recombinant) / GSK
Trial completion: A Study to Characterise Immune Responses Following Immunisations With "Fendrix" or "Engerix B" Hepatitis B Vaccines (clinicaltrials.gov) - Feb 8, 2016
P=N/A, N=30, Completed, Sponsor: University of Surrey
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Enrollment change: Proteomic Analysis of Human Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 6, 2016
P=N/A, N=5, Completed, Sponsor: Far Eastern Memorial Hospital
Active, not recruiting --> Completed Recruiting --> Completed | N=150 --> 5